Navigation Links
New and unique treatment for Psoriasis patients

Psoriasis patients who have been long-awaiting new options in treatment, now have fresh hope with the Food and Drug Administration's approval of the new drug, Amevive. This unique drug targets renegade immune cells to control hard-to-treat psoriasis. Psoriasis has been thought to occur when the immune system goes amok and cells called memory effector T cells prompt skin inflammation. The treatments that are currently available for psoriasis range from ointments to ultraviolet therapy to other injected drugs that can broadly suppress// the immune system. The new drug Amevive, however has been designed to target only the harmful T cells, instead of the entire immune system. Physicians have been eagerly awaiting the drug as it works differently from those drugs that are available in the market presently.

The drug, whose effect has not yet been compared with existing treatments, will be marketed in intravenous and intra-muscular injection forms. The treatment, for a 12-week course, will cost between $7000 and $10,000 and the weekly dose will be administered under the supervision of a doctor.

Biogen Inc., the makers of the drug, sponsored a study, which involved patients with chronic psoriasis that covered at least 10 percent of their bodies, and gave them either Amevive or dummy injections. They found that 40 per cent of patients on the Amevive drug saw their psoriasis symptoms cut in half, as compared to about 10 percent of placebo-treated patients. A small number of patients even saw their lesions almost vanish, for at least a while. Though the duration for which the effect lasted was not known, a small subset of patients went seven months or longer before needing additional treatment. The FDA's Dr. Karen Weiss cautioned that though the drug has a much more selective effect, it is still too soon to say it is very selective and very safe. In fact, she added that patients on the drug would require a blood test before each weekly dose to ensure the ir levels of infection-fighting immune cells have not dipped too low, which would require postponing a dose. Another theoretical concern is that by suppressing the immune system, the risk of cancer might increase. The FDA, while not restricting the number of times patients can repeat Amevive therapy when their psoriasis recurs, has warned that the effects of the drug on developing fetus is not yet known.


'"/>




Related medicine news :

1. A unique factor in breathing disorder
2. Pink Shawl Project is a unique initiative
3. Thyroid hormone treatment hastens recovery after cardiac surgery
4. Feeding channel created by malaria parasite - a new target for malaria treatments
5. Now umbilical cord helps in stroke treatment.
6. Now AIDS treatment comes dirt-cheap
7. Breast cancer treatment to be determined by gene test
8. Hemopurifier may revolutionise AIDS treatment
9. New drug helps boost cancer treatment
10. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
11. Experimental treatment for Ebola Virus Shows promising results in mice
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official ... (ILTM) show in Cannes (France), XO Private has initiated a second print-run of its ... measures almost a metre across when open, weighs in at more than six kilos, ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of genetic ... Pittsburgh points to eight genes that may explain why susceptibility to one of the ... of a study published today in the journal npj Schizophrenia. , “There is ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age is here, and ... that 47 percent of all jobs in the United States may be taken over ... day of the aggressive know-it-all who steamrolls over colleagues is drawing to a close. ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... hearing disabilities, it is so critically important that we all are aware of ... is why Mediaplanet is proud to announce the launch of its newest edition ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The narrative ... offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes the ... disorder and his attempts to overcome them. , Schanssema, initially unsure of the ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017 The U.S. Food and Drug ... Kit, performed on the Pheno System. This is ... bloodstream infections and provide information about which antibiotics ... sensitivity). The test also reduces the amount of ... which can guide antibiotic treatment recommendations more quickly. ...
(Date:2/24/2017)...  This report analyzes the worldwide markets for Chiral ... Products: Intermediates, Analytical, and Others. The End Use ... Agrochemicals. The report provides separate comprehensive analytics for the ... , and Rest of World. Annual estimates and ... Also, a six-year historic analysis is provided for these ...
(Date:2/24/2017)... , Feb 24, 2017 Research and ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... drug pricing data and benchmarks in the global Urinary Incontinence market. ... What are the key drugs marketed for Urinary Incontinence and ...
Breaking Medicine Technology: